REPLIGEN CORP Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value
REPLIGEN CORP (RGEN) had Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value of $0 as of 2017-12-31, per its 10-K filed 2018-02-22.
Discontinued › Notes › Fair Value Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue · last filed 2018-02-22
- 2017-12-31: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $0.00.
- 2017-03-31: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $0.00.
- 2016-12-31: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $6.12M.
- 2016-09-30: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $6.26M.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value as first filed |
|---|---|---|
| 2017-12-31 | $0.00 10-K · filed 2018-02-22 | |
| 2017-03-31 | $0.00 10-Q · filed 2017-05-04 | |
| 2016-12-31 | $6.12M 10-K · filed 2018-02-22 | |
| 2016-09-30 | $6.26M 10-Q · filed 2016-11-03 | |
| 2016-06-30 | $5.88M 10-Q · filed 2016-08-04 | |
| 2016-03-31 | $4.31M 10-Q · filed 2016-05-05 | |
| 2015-12-31 | $6.79M 10-K · filed 2017-02-23 | |
| 2015-09-30 | $4.82M 10-Q · filed 2015-11-05 | |
| 2015-06-30 | $4.59M 10-Q · filed 2015-08-06 | |
| 2015-03-31 | $3.84M 10-Q · filed 2015-05-08 | |
| 2014-12-31 | $3.84M 10-K · filed 2016-02-25 | $3.84M 10-K · filed 2015-03-17 |
| 2014-09-30 | $1.89M 10-Q · filed 2014-11-07 | |
| 2014-06-30 | $2.04M 10-Q · filed 2014-08-11 | |
| 2014-03-31 | $1.67M 10-Q · filed 2014-05-09 | |
| 2013-12-31 | $1.65M 10-K · filed 2015-03-17 | |
| 2013-09-30 | $1.60M 10-Q · filed 2013-11-08 | |
| 2013-06-30 | $1.54M 10-Q · filed 2013-08-07 | |
| 2013-03-31 | $1.51M 10-Q · filed 2013-05-07 | |
| 2012-12-31 | $2.90M 10-K · filed 2014-03-14 | |
| 2012-09-30 | $2.60M 10-Q · filed 2012-11-08 | |
| 2012-06-30 | $2.20M 10-Q · filed 2012-08-09 | |
| 2011-12-31 | $2.20M 10-K · filed 2013-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |